107133-36-8 Usage
Uses
Used in Pharmaceutical Industry:
Perindopril erbumine is used as an ACE inhibitor for the treatment of hypertension. It helps in lowering blood pressure by blocking the action of angiotensin-converting enzyme, which in turn reduces the production of angiotensin II, a potent vasoconstrictor.
Used in Antimicrobial Applications:
In the field of antimicrobials, perindopril erbumine is used as an antibacterial agent. It may exhibit properties that help in combating bacterial infections, contributing to the development of new treatments for various bacterial diseases.
Originator
Aceon ,Solvay Pharmaceuticals Inc. ,USA
Manufacturing Process
Heat 5 kg of 2-carboxyindole suspended in ethanol in the presence of sulfuric acid to boiling for 8 hours. Evaporate off take up the crystalline mass with hexane. After filtering off and drying, 5.3 kg of 2-ethoxycarbonylindole crystals are obtained. Melting point: 123°-125°C.Suspend, in a reactor, 10 kg of 2-ethoxycarbonylindoline obtained previously in 110 liters of hydrochloric ethanol. Next, add 20 kg of granulated tin. Keep stirring for approximately 2 days at room temperature. Evaporate off the ethanol, take up the residue with water and add 110 liters of toluene. Stir for approximately 20 min. Alkalify with aqueous ammonia. Separate off the aqueous phase and extract once again with 150 liters of toluene. Combine the toluene phases and wash them with water. Separate off the toluene phases, filter. Remove the water by distilling the water-toluene azeotrope. Cool and pass through a stream of anhydrous HCl gas. Cool. Evaporate down and wash with pure toluene. Weight obtained of (R,S)-2-ethoxycarbonylindoline 10.11 kg. Yield: 84%.2.15 kg of (R,S)-2-ethoxycarbonylindoline dissolved in ethanol are saponified with 12.5 liters of sodium hydroxide with stirring for 24 hours. After washing the alkaline solution, neutralize with concentrated hydrochloric acid. After filtering off, washing and drying, 1.57 kg of white crystals of the (R,S)-2carboxyindoline are obtained. Yield: 86%. Melting point: 188°-189°C.6.05 kg of (R,S)-2-carboxyindoline are added to a solution of 4.49 kg of (+)α-methylbenzylamine in anhydrous ethanol. A white precipitated product is obtained which, after filtering off, is digested in refluxing isopropanol. After cooling, the solid is filtered off and washed with a little isopropanol. 1 kg of the obtained salt was dissolved in 5 liters of water and neutralizing with an aqueous hydrochloric acid solution. The precipitate is filtered off, washed with water and dried and (S)-2-carboxyindoline was prepared.Place 25 kg of (S)-2-carboxyindoline, obtained previously, in 110 liters of methanol in a vessel. Keep stirred. Charge the rhodium (5% dry) catalyst into a mixer. Start up the stirring in a hydrogenator, charge the methanolic suspension of (S)-2-carboxyindoline by passing it through the mixer and rinse the assembly with water. Heat to 60°C and pressurize with hydrogen (30 bars). Filter off the catalyst on a single-plate filter. Collect the hydroalcoholic liquors in a reactor and evaporate the methanol off under vacuum. After concentrating, charge approximately 300 kg of dioxane. Heat to boiling and add water until a solution is obtained. Allow to cool. Filter off and dry. 22.3 kg of crystals of (2S,3aS,7aS)-2-carboxyoctahydroindole are obtained. Yield: 86.1%.Place 35 kg of L-norvaline in approximately 300 kg of denatured ethanol in a reactor. Introduce approximately 60 kg of thionyl chloride, slowly and gradually. After stirring for a quarter of an hour, heat to reflux for 3 hours andthen evaporate off the ethanol under vacuum. Take up the residue with 300 liters of cyclohexane and heat to boiling. Allow to cool, filter, wash with cyclohexane and dry. 52.9 kg of ethyl L-norvalinate hydrochloride are obtained, that is a 97.6% yield.Place 45 kg of ethyl N-norvalinate hydrochloride approximately 110 liters of water in a vessel equipped with a stirrer. Alkalify, then pour 23 kg of pyruvic acid very gradually into the solution obtained previously and stir the reaction mixture for 30 min. Place an aqueous suspension of charcoal containing 5% palladium and the alkaline solution of ethyl L-norvalinate obtained previously in a hydrogenation apparatus. Hydrogenate under pressure (30 bars) at room temperature for approximately one day. Filter under vacuum and evaporate the filtrate under reduced pressure, filter off and dry. Treat the residue obtained with ethanol; remove the insoluble material, consisting of sodium chloride, by filtration and rinse it with ethanol. Combine the ethanolic solutions; evaporate off the ethanol under reduced pressure and crystallize the residue from acetonitrile 34.3 kg of N-[(S)-1-carbethoxybutyl]-(S)-alanine are obtained, that is a 63.9% yield.In a 30-liter reactor, reflux 12.5 kg of (2S,3aS,7aS)-2-carboxyperhydroindole, 50 kg of para-toluenesulfonic acid and 14.2 kg of benzyl alcohol and 38.4 kg of toluene, removing the water formed with the aid of a continuous separator. When no more water separates out, cool, filter off the precipitate of paratoluenesulfonate of the benzyl ester of (2S,3aS,7aS)-2carboxyoctahydroindole formed, and dry. Yield: 91.3%.Add approximately 3.5 kg of triethylamine to a suspension of approximately 5 kg of para-toluenesulfonate of the benzyl ester of (2S,3aS,7aS)-2carboxyoctahydroindole in approximately 60 kg of ethyl acetate, followed by approximately 6 kg of 1-hydroxybenzotriazole, approximately 7.5 kg of the N[(S)-1-carbethoxybutyl]-(S)-alanine and approximately 7.0 kg of dicyclohexylcarbodiimide. Stir, cooling slightly for approximately 3 hours, then filter off the dicyclohexylurea formed and wash the organic phase with water. The dried organic phase is evaporated to dryness and benzyl ester of (2S,3aS,7aS)-1-{2-[1-(ethoxycarbonyl)-(S)-butylamino]-(S)propionyl}octahydroindole-2-carboxylic acid was obtained. Yield: 92.3%.Dissolve, in a hydrogenator, 14 kg of benzyl ester of the (2S,3aS,7aS)-1-{2[1-(ethoxycarbonyl)-(S)-butylamino]-(S)-propionyl}octahydroindole-2carboxylic acid in cyclohexane. Add the charcoal containing 5% palladium and approximately 50 liters of water. Hydrogenate at ordinary temperature and pressure until the theoretical volume of hydrogen has been absorbed. Filter, wash the insoluble material with cyclohexane, separate off the organic phase and wash the aqueous phase again with cyclohexane. Isolate the (2S,3aS,7aS)-1-{2-[1-(ethoxycarbonyl)-(S)-butylamino]-(S)propionyl}octahydroindole-2-carboxylic acid from the aqueous phase by freeze-drying.In practice it is used combined with 2-methyl-2-propanamine.
Therapeutic Function
Antihypertensive
Biochem/physiol Actions
Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive; becomes hydrolyzed in vivo to the active diacid metabolite; unlike the other ACE inhibitors, inhibits tumor growth in hepatocellular carcinoma cells due to suppression of VEGF levels; also suppresses angiotensin II production in vitro. Long-term therapy with this agent has a beneficial effect on the cerebral circulation by improving cerebral perfusion reserve in patients with previous minor stroke.
Safety Profile
A poison by intravenous route. Moderately toxic by ingestion, When heated to decomposition it emits toxic vapors of NOx.
Check Digit Verification of cas no
The CAS Registry Mumber 107133-36-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,1,3 and 3 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 107133-36:
(8*1)+(7*0)+(6*7)+(5*1)+(4*3)+(3*3)+(2*3)+(1*6)=88
88 % 10 = 8
So 107133-36-8 is a valid CAS Registry Number.
InChI:InChI=1/C19H32N2O5.C4H11N/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3/t12-,13-,14?,15-,16-;/m0./s1
107133-36-8Relevant articles and documents
Of enantiomerically enriched indoline - 2 - formic acid
-
Paragraph 0145; 0146; 0147; 0148, (2017/09/01)
The invention discloses a synthesis method of enantiomer-enriched indoline-2-formic acid shown in a formula (I). The synthesis method of the enantiomer-enriched indoline-2-formic acid comprises the following steps: by adopting low-cost and available ortho-position halogen substituted benzaldehyde and N-benzoyl substituted glycine as starting materials, carrying out Erlenmeyer-Plochl cyclization, alkaline hydrolysis and asymmetric catalytic hydrogen for constructing a chiral center, and then carrying out acid catalysis, deprotection and cyclization sequentially or cyclization, acid catalysis and deprotection sequentially, so that the enantiomer-enriched indoline-2-formic acid is obtained. The synthesis method of the enantiomer-enriched indoline-2-formic acid has the advantages that raw materials used in the whole process route are low-cost and easily available, harmful substances or multiple danger special processes are not used, reaction conditions are mild, technological operation is simple, production is safe and stable, the product yield is high, the purity is high, less three wastes are produced, and the energy consumption is low, so that the synthesis method of the enantiomer-enriched indoline-2-formic acid is a process route especially applicable to industrial production. The formula (1) is described in the specification.
PROCESS FOR THE PREPARATION OF PERINDOPRIL ERBUMINE SALT AND NOVEL POLYMORPH (S) THEREOF
-
Page/Page column 12; 12-13, (2008/12/07)
A single pot process for the preparation of perindopril erbumine salt according to which condensation of (2S, 3aS, 7aS)-octahydroindole-2-carboxylic acid benzyl ester para toluene sulfonate with N-((S-)-ethoxy carbonyl -1-ethyl-(S)-alanine, catalytic hydrogenation of benzyl ester of (2S, 3aS, 7aS)-1-{2-[1-(ethoxycarbonyl)-(S)-butylamino]-(S)propionyl}- octahydro-indole-2-carboxylate and conversion of (2S,3aS, 7aS)-1-{2-[1-ethoxycarbonyl)_(S)-butylamino]-(S)-propionyl}octahydroindole-2-carboxylic acid to its perindopril erbumine salt are carried out in a single pot using a single solvent such as isopropyl acetate to obtain perindopril erbumine salt of very high purity. Also a novel polymorph S of perindopril erbumine having X-ray diffraction peaks of 9.10, 14.64, 15.37, 16.58, 17.39, 19.99, 20.62, 21.50, 22.15, 22.60, 24.20, 27.55 ± 0.2 at 2Θ values. Also processes for preparing the novel polymorph S.
SALTS OF PERINDOPRIL
-
Page/Page column 15-16, (2009/03/07)
The present invention relates to new salts of perindopril, particularly to a new calcium salt and new amine salts of perindopril, to a process for their preparation and to a pharmaceutical formulations containing the new salts.
NEW CRYSTALLINE FORM OF PERINDOPRIL ERBUMINE
-
Page/Page column 9, (2008/06/13)
The present invention relates to new crystalline form of the ACE inhibitor perindopril and processes for the preparation thereof.
NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF
-
Page/Page column 2, (2008/06/13)
Process for the synthesis of perindopril of formula (I): and its pharmaceutically acceptable salts.
PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
Page/Page column 2, (2008/06/13)
A process for the synthesis of perindopril of formula (I): and its pharmaceutically acceptable salts.
PROCESS FOR SYNTHESIS OF PERINDOPRIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.
-
Page/Page column 3, (2008/06/13)
Process for the synthesis of perindopril of formula (I): and pharmaceutically acceptable salts thereof.
Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof.
-
Page/Page column 2, (2010/11/26)
Process for the industrial synthesis of perindopril of formula (I): and pharmaceutically acceptable salts thereof.
Process for the preparation of perindopril and salts thereof
-
Page/Page column 12-13, (2008/06/13)
The present invention describes a novel method for the synthesis of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid, or of one of its aryl esters of formula XIII wherein X and Y are a hydrogen atom, a halogen, alkyl, alkoxyl or nitro group, and the conversion of the paranitrobenzyl ester of formula X into Perindopril of formula I or one of its salts.
PROCESS FOR THE PREPARATION OF PERINDOPRIL
-
Page/Page column 12, (2008/06/13)
The present invention relates to an improved process for the preparation of silylated (2S, 3aS, 7aS)-2-carboxyperhydroindole. Also provided is an improved process for the preparation of perindopril and its pharmaceutically acceptable salts.
